MUC16 and ovarian cancer: By combining next-generation sequencing of serum miRNAs with machine learning techniques, neural network analysis has the ability to identify more stage I/II ovarian cancers with a significantly lower false-positive rate, as well as identifying borderline tumors much better than CA125 (45).